Does the media prefer HHH or TSHA?

In the previous week, Howard Hughes had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Howard Hughes and 4 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.84 beat Taysha Gene Therapies' score of 0.33 indicating that Howard Hughes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Howard Hughes 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is COGT or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.07% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Taysha Gene Therapies N/A -56.07% -40.16%

Does the media favor COGT or TSHA?

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Taysha Gene Therapies' score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TSHA or MIRM?

In the previous week, Mirum Pharmaceuticals had 29 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 33 mentions for Mirum Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Mirum Pharmaceuticals' score of 0.05 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CGON or TSHA?

In the previous week, CG Oncology had 21 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 25 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat CG Oncology's score of 0.01 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSHA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.52% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.07% -40.16% Xenon Pharmaceuticals N/A -49.52% -46.72%

Does the media refer more to TSHA or XENE?

In the previous week, Xenon Pharmaceuticals had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Taysha Gene Therapies' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Taysha Gene Therapies (TSHA) Competitors

$6.56 +0.22 (+3.47%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$6.47 -0.09 (-1.31%)

As of 08/7/2026 07:55 PM Eastern

Compare

TSHA vs. HHH, COGT, MIRM, CGON, and XENE

Should you buy Taysha Gene Therapies stock or one of its competitors? MarketBeat compares Taysha Gene Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Taysha Gene Therapies include Howard Hughes (HHH), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), and Xenon Pharmaceuticals (XENE).

How does Taysha Gene Therapies compare to Howard Hughes?

Howard Hughes (NYSE:HHH) and Taysha Gene Therapies (NASDAQ:TSHA) are related companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Howard Hughes	$1.47B	2.73	$131.88M	$4.94	13.67
Taysha Gene Therapies	$7.47M	252.32	-$109M	-$0.38	N/A

In the previous week, Howard Hughes had 8 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Howard Hughes and 4 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.84 beat Taysha Gene Therapies' score of 0.33 indicating that Howard Hughes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Howard Hughes	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Howard Hughes has a net margin of 12.31% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 9.91% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Howard Hughes	12.31%	9.91%	2.93%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

93.8% of Howard Hughes shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 48.0% of Howard Hughes shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Howard Hughes currently has a consensus target price of $79.00, suggesting a potential upside of 16.98%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 94.65%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Howard Hughes	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Howard Hughes has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Summary

Howard Hughes beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Taysha Gene Therapies' return on equity of -56.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Taysha Gene Therapies has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Taysha Gene Therapies	$7.47M	252.32	-$109M	-$0.38	N/A

Cogent Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Taysha Gene Therapies' score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.7% of Taysha Gene Therapies shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cogent Biosciences presently has a consensus target price of $45.90, suggesting a potential upside of 8.28%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 94.65%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Cogent Biosciences on 12 of the 14 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Taysha Gene Therapies (NASDAQ:TSHA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Taysha Gene Therapies has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Mirum Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$7.47M	252.32	-$109M	-$0.38	N/A
Mirum Pharmaceuticals	$618.07M	9.93	-$23.36M	-$14.55	N/A

Taysha Gene Therapies has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Taysha Gene Therapies currently has a consensus price target of $12.77, suggesting a potential upside of 94.65%. Mirum Pharmaceuticals has a consensus price target of $137.33, suggesting a potential upside of 36.45%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 29 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 33 mentions for Mirum Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Mirum Pharmaceuticals' score of 0.05 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Taysha Gene Therapies beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Taysha Gene Therapies has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$6.23M	1,063.58	-$160.99M	-$2.69	N/A
Taysha Gene Therapies	$7.47M	252.32	-$109M	-$0.38	N/A

In the previous week, CG Oncology had 21 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 25 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat CG Oncology's score of 0.01 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-26.58%	-25.34%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

CG Oncology currently has a consensus target price of $83.18, suggesting a potential upside of 10.76%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 94.65%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Taysha Gene Therapies (NASDAQ:TSHA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Taysha Gene Therapies has higher earnings, but lower revenue than Xenon Pharmaceuticals. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$7.47M	252.32	-$109M	-$0.38	N/A
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A

Taysha Gene Therapies currently has a consensus price target of $12.77, indicating a potential upside of 94.65%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Taysha Gene Therapies' higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Taysha Gene Therapies has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Xenon Pharmaceuticals' return on equity of -49.52% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Xenon Pharmaceuticals	N/A	-49.52%	-46.72%

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Taysha Gene Therapies' score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Taysha Gene Therapies on 8 of the 14 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.89B	$3.69B	$7.01B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-17.26	9.02	271.11	25.19
Price / Sales	252.32	1,290.90	595.59	79.93
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	7.29	18.10	13.25	6.22
Net Income	-$109M	-$13.25M	$3.45B	$342.66M
7 Day Performance	11.95%	6.24%	4.67%	4.41%
1 Month Performance	-0.15%	-3.50%	-1.28%	-1.10%
1 Year Performance	141.18%	61.28%	77.33%	23.99%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	2.6906 of 5 stars	$6.56 +3.5%	$12.77 +94.7%	+141.2%	$1.89B	$7.47M	N/A	180	Upcoming Earnings
HHH Howard Hughes	3.0568 of 5 stars	$65.15 +1.9%	$79.00 +21.3%	-5.1%	$3.81B	$1.47B	31.93	608	News Coverage Positive News Earnings Report Analyst Upgrade
COGT Cogent Biosciences	1.4563 of 5 stars	$38.86 -0.2%	$45.90 +18.1%	+286.8%	$6.65B	N/A	N/A	80	Positive News Upcoming Earnings
MIRM Mirum Pharmaceuticals	2.9316 of 5 stars	$104.59 -1.3%	$143.40 +37.1%	+67.8%	$6.46B	$521.31M	N/A	140	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
CGON CG Oncology	2.1862 of 5 stars	$69.15 -2.9%	$81.73 +18.2%	+202.2%	$6.28B	$4.04M	N/A	61	Trending News Earnings Report Analyst Forecast Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, COGT, MIRM, CGON, and XENE

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Cogent Biosciences?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Summary

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, COGT, MIRM, CGON, and XENE

How does Taysha Gene Therapies compare to Howard Hughes?

Which has stronger earnings and valuation, HHH or TSHA?

Does the media prefer HHH or TSHA?

Is HHH or TSHA more profitable?

Do institutionals & insiders believe in HHH or TSHA?

Do analysts rate HHH or TSHA?

Which has more volatility and risk, HHH or TSHA?

Summary

How does Taysha Gene Therapies compare to Cogent Biosciences?

Is COGT or TSHA more profitable?

Which has higher earnings & valuation, COGT or TSHA?

Which has more volatility and risk, COGT or TSHA?

Does the media favor COGT or TSHA?

Do institutionals and insiders hold more shares of COGT or TSHA?

Do analysts recommend COGT or TSHA?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Is TSHA or MIRM more profitable?

Which has preferable valuation & earnings, TSHA or MIRM?

Which has more risk & volatility, TSHA or MIRM?

Do analysts prefer TSHA or MIRM?

Do institutionals & insiders hold more shares of TSHA or MIRM?

Does the media favor TSHA or MIRM?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Which has stronger earnings & valuation, CGON or TSHA?

Does the media prefer CGON or TSHA?

Do institutionals and insiders have more ownership in CGON or TSHA?

Which has more risk & volatility, CGON or TSHA?

Is CGON or TSHA more profitable?

Do analysts rate CGON or TSHA?

Summary

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Which has preferable earnings & valuation, TSHA or XENE?

Do analysts recommend TSHA or XENE?

Which has more volatility & risk, TSHA or XENE?

Is TSHA or XENE more profitable?

Do insiders and institutionals have more ownership in TSHA or XENE?

Does the media refer more to TSHA or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools